

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

https://marketpublishers.com/r/GCE08D749E0EN.html

Date: January 2014

Pages: 145

Price: US\$ 2,500.00 (Single User License)

ID: GCE08D749E0EN

Abstracts

Positive sentiments for the biotech sector have prevailed in the last two to three years, and we expect this trend to continue for the next year too. Our optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space.

In the next five years the distinction between some mature biotech companies and large global pharma may become blurred esp. if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira's infliximab – Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway is defined in US.

The detailed 72 pages report contains the detailed discussion of the key attributes of leading biotech companies' Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex.

Key Words: Tags: Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva, obinutuzumab, GA-101, ELOCTATE, ALPROLIX, Hemophilia A, Hemophilia B, Factor VIIIFc, Factor IXFc, Pomalidomide, POMALYST, Carfilzomib, ABRAXANE,



Sotatercept, ACE-536, CC-292, MOR202, Stribild, Complera, Idelalisib, DART, Sovaldi, Sovaldi, Interferon-free treatment, Sofosbuvir/ Ledispavir, Eylea, Aflibercept, VEGF-Trap Eye, wet-AMD, Arcalyst, ZALTRAP, Alirocumab, INCIVEK, KALYDECO, KAKALYDECO/VX-809, VX-509, VX-787, VX-767, Cystic Fibrosis, G551D mutation, del508 Mutation



Contents

MACRO ANALYSIS

Key Attributes of Leading Biotech Companies New Drug Approval in 2013-16 Key Milestones during 2014/15 Merger and Acquisitions Biosimilars in developments

IN-DEPTH COMPANY ANALYSIS AND REPORTS ON

1. ACORDA THERAPEUTICS – PIPELINE OF NDDS DRUGS TARGETING NICHE INDICATIONS

Marketed Products - Ampyra and Qutenza Label expansion of Ampyra Pipeline beyond Ampyra

2. ALEXION PHARMA – FOCUS ON INNOVATIVE DRUGS FOR ORPHAN/ ULTRA-RARE DISEASES WITH NO COMPETITION VISIBLE!

Product Pipeline – Future Potential
Soliris in PNH and aHUS: Growth to Continue
Soliris beyond PNH and aHUS
Diversifying Beyond Soliris - Asfotase alfa
Early stage programs – Cyclic Pyranopterin Monophosphate, ALXN1007, ALXN1102

3. AMGEN – LATE-STAGE PIPELINE CARRIES POTENTIAL TO COUNTERACT EXPECTED HEADWINDS

Late-Stage Pipeline
Biosimilar Opportunity & Competition
Partnership and Acquisitions
Competitive Landscape: Anti-PCSK9 mAb – Hyperlipidemia

4. BIOGEN IDEC – NEAR-TERM GROWTH PROSPECTS DRIVEN BY CORE BUSINESS + NEW PRODUCT LAUNCHES



TECFIDERA

Long-Acting Hemophilia Drugs – ELOCTATE and ALPROLIX
Detailed data from long-lasting recombinant FVIII and FIX
Superiority of Gazyva against Rituxan in CLL
BIIB's MS Franchise – Strengthening its Leadership

MULTIPLE SCLEROSIS – INJEC Table DRUGS DATA COMPARISON

MULTIPLE SCLEROSIS – ORAL DRUGS DATA COMPARISON

5. CELGENE – INNOVATIVE STRATEGIES FOR LONG TERM GAINS

Growth from marketed products and label expansion of Revlimid, ABRAXANE, POMALYST/IMNOVID, Vidaza

Novel Early Stage Products - Sotatercept, ACE-536, CC-292, MOR202, CC-223, EPZ5676, CC-220

Collaborations

6. GILEAD SCIENCES - POISED TO EMERGE AS A LEADER IN HCV TREATMENT

Sofosbuvir/ Ledispavir FDC

Development Pipeline

HIV Life cycle management

Beyond Anti-Virals – Idelalisib, Momelotinib, Simtuzumab, GS-9973

Acquisitions

Technology platform – Dual-Afnity Re-Targeting (DART)

7. REGENERON – LABEL EXPANSION SUSTAINS EYLEA'S GROWTH MOMENTUM + LATE STAGE PIPELINE

Potential Poised For Further Contribution

Marketed Products – Eylea, Arcalyst, ZALTRAP

Label expansion of Eylea in DME and BRVO indication

Late-Stage Pipeline - Alirocumab, Sarilumab, Dupilumab

REGN-Sano Collaboration

BRANCH RETINAL VEIN OCCLUSION (BRVO): CLINICAL DATA ANALYSIS



COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB - HYPERLIPIDEMIA

8. VERTEX PHARMA – FOCUS SHIFT TO CYSTIC FIBROSIS AND NICHE INDICATIONS

Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation

Small But Meaningful Addition in Other Mutations for KALYDECO

PhII data from KALYDECO / VX-809

PHIII studies for KALYDECO and VX-809/KALYDECO in homozygous CF pts

HCV Glory Faded Very Soon

Beyond CF and HCV - VX-509, VX-787, VX-767

KEY Pipeline Products: IFN-Free Combinations for HCV

- 1. Pipeline Potential Thru 2018
- 2. Marketed Products' Potential
- 3. Sector Selected Companies M&A Activities
- 4. Expected Drug Clinical Milestones



I would like to order

Product name: Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Product link: https://marketpublishers.com/r/GCE08D749E0EN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GCE08D749E0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970